US Biotech Industry to Witness Fast Growth

According to our new research report “US Biotech Market Analysis”, the US has continued to dominate the global biotechnology industry for the past few years. Fuelled by factors like, strong support of industry players through funding and investment and new drug development for various diseases, the US biotech industry reached the mark of US$ 72 Billion in 2009. Despite recession, the industry continued to perform well and contributed a large share in the global biotech industry. In future, the US biotech industry is expected to grow at the CAGR of 7% during 2009-2013 to reach US$ 95 Billion by 2013.

Our report has found that, financing remains an important factor for the US biotech sector as various numbers of projects for drug development and other related fields need capital. Moreover, companies are looking for funds that can strengthen their market share in the industry. Of various means for capital, venture funding has remained a key source that backed the industry in recession also. The amount and level of financing is expected to grow in near future as companies are gearing up for new research and product portfolios.

“US Biotech Market Analysis” covers various aspects of the US biotech industry and analyzes key information in an effective manner. The report presents current market trends that are expected to impact industry scenario in near future. These trends have been identified after an in-depth analysis of recent developments that took place in the industry. Sections like biotech funding and clinical trials are the illustration of key driver and fast growing segments respectively.

The report is an outcome of an in-depth research and prudent analysis of the US biotech industry with special focus on easy to understand content and effective presentation. The report provides forecast for key areas and the use of reliable methods and techniques make the future outlook more realistic. Description of key active players and their recent activities have also been provided. Overall, the report is expected to facilitate the decision making process for investors and clients.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM0300.htm

Check DISCOUNTED REPORTS on: http://www.rncos.com/promotion.htm